Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

PURPOSE: Vorinostat has been shown to overcome resistance to gefitinib. We performed a phase I/II study combining gefitinib with vorinostat in previously treated non-small cell lung cancer (NSCLC). METHODS: A 3 + 3 dose-escalation design was used to determine maximum tolerated dose (MTD) and recomme...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ji-Youn, Lee, Soo Hyun, Lee, Geon Kook, Yun, Tak, Lee, Young Joo, Hwang, Kum Hui, Kim, Jin Young, Kim, Heung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341018/
https://www.ncbi.nlm.nih.gov/pubmed/25552401
http://dx.doi.org/10.1007/s00280-014-2664-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341018/
https://www.ncbi.nlm.nih.gov/pubmed/25552401
http://dx.doi.org/10.1007/s00280-014-2664-9

Ejemplares similares